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Pharmaceutical abdominal aortic aneurysm stabilization is an unmet medical need. To date, over numerous
clinical and hundreds, of pre-clinical papers show the potential of numerous interventions. Yet conclusions from
clinical reports are not fully consistent. As such, a systematic review of the available clinical data is relevant.Background: Management of abdominal aortic aneurysms (AAAs) relies on surgical repair of larger AAAs.
Consequently medical interventions inhibiting AAA progression could greatly reduce the need for surgical repair.
A spectrum of pharmaceutical strategies has been reported, albeit conclusions often appear contradictory. Given
the longstanding interest in pharmaceutical AAA stabilization, a systematic review of the available literature is
relevant.
Objectives: The aim is to provide an up to date systematic review of the available data on pharmaceutical
therapies for stabilizing or impeding AAA growth.
Methods: A search using Pubmed, Embase, Web of science, Cochrane, CINAHL, Academic Search Premier, and
Science Direct identiﬁed 27 eligible papers that studied the clinical effect of the pharmaceutical therapy on AAA
diameter growth.
Results: This review shows that there is currently no pharmaceutical strategy that reduces AAA growth. Most
studies are of poor methodological quality. Initial promising reports are often not conﬁrmed in subsequent larger
studies, raising the possibility of selective reporting.
Conclusion: There is currently no pharmaceutical means that halts AAA growth.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The risk of rupture of an abdominal aortic aneurysm (AAA)
progressively increases in larger AAAs > 55 mm. Four large
clinical trials have not shown a beneﬁt of earlier repair1 (i.e.
for aneurysms <55 mm). Therefore, the therapeutic
approach to AAAs is surveillance of small aneurysms and
prophylactic surgical open or endovascular aneurysm repair
(EVAR) in AAAs over 55 mm.2 Yet while open repair has
excellent long-term outcomes, it has a signiﬁcant peri-responding author. Department of Vascular Surgery, Leiden
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//dx.doi.org/10.1016/j.ejvs.2015.08.010operative morbidity and mortality. Although EVAR comes
with a signiﬁcantly lower peri-operative morbidity and
mortality, its cost effectiveness is being questioned.
Consequently, a pharmaceutical means of slowing down or
stabilizing the progression of small AAAs, and thus post-
poning or obviating the need for surgery could provide a
major advance.3 In fact, pharmaceutical stabilization of AAA
is now considered an unmet medical need.
A large body of preclinical evidence has shown that
interference with aspects of vascular inﬂammation and/or
proteolytic activity alleviates AAA formation in rodent
models of the disease.4,5 Clinical studies, on the other
hand, are limited and their conclusions often inconsis-
tent.6e8 The clinical evidence has been reviewed in 78
papers (from a systematic literature search), yet a
comprehensive systematic review is missing. Given the
renewed interest in pharmaceutical AAA stabilization, a
Figure 1. Systematic search strategy. First selection on title, second
on abstract, and last selection was made by reading the full article.
Small Abdominal Aortic Aneurysms 703systematic review of the available evidence on pharma-
ceutical interventions for stabilizing or impeding AAA
growth in humans is relevant.
METHODS
Search strategy
The studies included in this review were identiﬁed from
PubMed, Embase, Web of science, Cochrane, CINAHL, Aca-
demic Search Premier, and Science Direct. The search was
not limited, and thus all languages and publication types
(e.g. reviews or conference abstracts) were included. The
search was most recently updated on April 17, 2015.
Two search themes were created, which were combined
in the search by AND. The ﬁrst theme was created for AAAs
by using all terms for abdominal aortic aneurysm, such as
abdominal aneurysm or abdominal aorta aneurysm. The
second term consisted of all terms for pharmacology,
including speciﬁc drug group names, such as medical
treatment or drugs or hydroxymethylglutaryl-coA reductase
inhibitors. Details of the search strategy are available in the
supplementary data.
Inclusion criteria
Only studies providing original clinical data on an effect of
pharmaceutical therapy on AAA growth were included.
Hence, all animal studies and studies that exclusively
described an effect of pharmaceutical intervention on mo-
lecular processes in the aneurysm wall; all reviews (n ¼ 79)
and commentaries were excluded.
Two authors (V.K. and J.L.) independently reviewed the
results of the search strategy. A ﬁrst selection was made on
title; all articles potentially reporting an effect of a phar-
maceutical intervention on AAA disease were included. A
second selection was made by reading the abstract of ar-
ticles that were selected on the basis of the title. The ﬁnal
selection was made on basis of the full text.
The quality of the identiﬁed studies was scored using the
STROBE scoring system.9
Statistical analysis was not performed because of the
marked heterogeneity of the included studies.
RESULTS
The search strategies identiﬁed 3,557 articles. Selecting title
and abstract narrowed the number of articles to 30 original
studies. Two of the 30 original studies were excluded
because of missing data on the AAA growth rate.10,11
Another article, written in Danish,12 was excluded since it
was also published separately in English.13 As a result, 27
original articles were available for this review (Fig. 1).
Identiﬁed studies are summarized in Table 1 and their
quality assessed (STROBE scoring system,9 Supplementary
Table).
Antihypertensive drugs
Beta blockers and other antihypertensive drugs were the
ﬁrst agents to be evaluated for their potential to reduce theAAA expansion rate. Beta blockers were evaluated in two
randomized controlled trials (RCTs),14,15 three case control
studies,16e18 and two cohort studies.19,21 The two earliest,
very small studies (n ¼ 38 and n ¼ 12 cases) suggested a
borderline signiﬁcant effect of beta blockers on aneurysm
expansion rate.17,18 Later cohort studies, however, found no
effect of beta blockers on the growth rate of AAAs.16,18,21
Similar to this, the two RCTs did not show an effect of
propranolol treatment on AAA expansion.14,15 Importantly,
both RCTs concluded that the drug propranolol is poorly
tolerated, with a 42% drop out rate in the propranolol
group.14
There are several reports on other classes of hyperten-
sives. A retrospective study suggesting an effect of angio-
tensin converting enzyme (ACE) inhibition on AAA stability20
was followed by ﬁve studies investigating an effect of ACE
inhibitors on AAA growth. Four of these studies, two small
retrospective analyses within a prospective case control
study16,21 and two larger retrospective studies (n ¼ 1231
and n ¼ 242 cases) found no effect of ACE inhibitors on
aneurysm expansion.21,22 In contrast, a recent prospective
cohort study of 1701 patients participating in the UK small
aneurysm trial, unexpectedly indicated a signiﬁcant increase
in aneurysm growth rate in patients taking ACE inhibitors,
Table 1. Full survey of all articles included in this systematic review.
First author/trial Year Intervention Study design Participants
(Cases/Controls)
Outcomes Signiﬁcance Strobe
score
Study qualities Study limitations
PATI14 2002 Propranolol RCT Total: 548 AAA diameter growth
(mm/y):
NS 1. Study medication
was randomly and
double blinded
assigned
1. Slow growing AAAs
and patients already
using beta blockers
excluded
(276/272) Cases: 2.02 2. Valid power
calculation
2. Low compliance,
high drop out rate:
26.8% and 42.4% of
the patients in the
placebo arm and the
propanolol arm
stopped their
medication
Controls: 2.60 3. Mislabeling of a
batch of study
medication
4. No correction for
non-random drop out
Lindholt15 1999 Propranolol RCT Total: 54 Relative risk of expansion: NS 1. Study medication
was randomly and
double blinded
assigned
1. High drop out rate:
60% and 25% of the
patients in the
propranolol and
placebo arm stopped
their medication
(30/24) Cases: 2.44 (0.88e6.77) 2. Power calculation
missing
Controls: 1.17 (0.74
e1.85)
Wilmink16 2002 Antihypertensive
drugs:
Prospective case
control study
Total: 5811 AAA diameter growth
(mm/y):
13.5/22 1. Large study size 1. Observational study,
data derived from two
separate screening
populations with
different baseline
characteristics
Calcium channel
blockers
(48/284) Cases: 0.5 NS 2. Limited number of
cases
Controls: 0.8 3. Power calculation
missing
ACE inhibitors (24/308) Cases: 0.02 NS 4. No correction for
non random drop out
Controls: 0.8
Diuretics (54/278) Cases: 0.8 NS
Controls: 0.7
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Beta blockers (77/255) Cases: 0.8 NS
Controls: 0.7
Gadowski17 1994 Beta blockers Prospective case
control study
Total: 111 AAA diameter growth
(mm/y)
NS 11.5/22 1 Long-term follow up 1. Observational study
(38/83) Cases: 3.0 2. Heterogeneous with
respect to type and
dose of beta blocker
Controls: 4.4
Leach18 1988 Beta blockers Retrospective
case control
study
Total: 27 AAA diameter growth
(mm/y)
NS 11.5/22 1. Observational study
(12/15) Cases: 1.7 2. Retrospective study
Controls: 4.4 3. Limited number of
cases
Bhak19 2015 Prospective
cohort study
Total: 534 Adjusted difference in
AAA diameter growth
(mm/y)
p ¼ .004 14.5/22 1 Large number of
o erall participants
1. Number of patients
per group unclear
Beta blockers unclear 0.009 .51 2. Observational study
Cholesterol
lowering
unclear 0.02 .18 3. Both CT and
ultrasound
measurements
Antihypertensive unclear 0.001 .78
Aspirin unclear 0.01 .48
Kortekaas21 2014 ACE inhibitors Prospective case
control study
Total: 286 Difference in growth rate:
0.24 mm/year
p > .05 16.5/22 1 Single observer
m asurements only
1. Observational study
(82/286) 2. Signiﬁcant
difference in baseline
characteristics
3. Power calculation
missing
Thompson22 2010 Prospective
cohort study
Total: 1231 Difference in AAA
diameter growth between
cases and controls (mm/
y):
1 Large study size 1. Patients lost to
follow (n ¼ 158) up
had a signiﬁcantly
lower AAA growth rate
ACE inhibitors 294 ACE inhibitors: 0.28 NS 2. Time effect, patients
identiﬁed between
1984 and 2007
Statins 383 Statins: 0.29 NS 3. No correction for
non-random drop out
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Table 1-continued
First author/trial Year Intervention Study design Participants
(Cases/Controls)
Outcomes Signiﬁcance Strobe
score
Study qualities Study limitations
4. Secondary analysis,
study not powered for
an evaluation of an
ACE inhibitor or statin
effect
Sweeting23 2010 Prospective
cohort study
Total: 1701 AAA diameter growth
(mm/y)
1. Large study size 1. Observational study
ACE inhibitors 169 Cases: 3.33 p ¼ .009 2. Long-term follow up 2. Patients included
between 1991 and
1995
Controls: 2.77 3. Data partially
adjusted and fully
adjusted available
Calcium Channel
Blockers
440 Cases: 2.76 NS
Controls: 2.5
Beta Blockers 255 Cases: 2.70 NS
Controls: 2.85
Statins 21 Cases: 2.07 NS
Controls: 2.84
Anti Platelet
Therapy
501 Cases: 2.89 NS
Controls: 2.80
Periard24 2012 Statins Retrospective
case control
study
Total: 94 AAA diameter growth
(mm/y)
p ¼ .01 17.5/22 1. Observational study
(50/44) Cases: 2.93 2. Retrospective study
Controls: 4.39 3. Uncommon
deﬁnition of AAA
(>25 mm)
4. Limited number of
size measures
5. A higher number of
CT estimates (over
estimates AAA size) in
the non-statin group
Karrowni25 2011 Statins Retrospective
case control
study
Total: 211 AAA diameter growth
(mm/y)
p < .001 15.5/22 1. AAA patients who at
follow up were found
to have a change in
statin therapy were
excluded
1. Observational study
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(136/75) Cases: 0.9 2. Retrospective study
Controls: 3.2 3. Mixed imaging
modalities and absent
deﬁnition of max.
diameter
4. Only 10% of the
patients was imaged at
3 or more occasions
Karrlson26 2009 Statins Retrospective
case control
study
Total: 213 AAA diameter growth
(mm/y):
p ¼ .008 9.5/22 1 Consistent aortic
d meter
m asurements via
u rasound
1. Observational study
(85/128) Cases: 1.6 2. Retrospective study
Controls: 2.5 3. Sub-analysis of a
studying evaluating an
effect of azithromycin
4. Details regarding
statin therapy missing
Schlosser27 2008 Statins Prospective case
control study
Total: 147 Adjusted estimated
difference in growth rate
for statin use: 1.2 mm/
year
p ¼ .021 16.5/22 1 AAA expansion rates
w re adjusted for age,
i tial AAA diameter,
a d hyperlipidemia in
t multivariate linear
r ression model
1. Observational study
(63/84) 2. Retrospective study
3. Time effect,
inclusion window 1996
e2007
Schouten28 2006 Statins Retrospective
case control
study
Total: 150 Adjusted estimated
difference in growth rate
for statin use: 1.6 mm/
year
p ¼ .006 16.5/22 1 Patients with an
i ammatory (n ¼ 12)
a d mycotic (n ¼ 1)
A A were excluded
1. Observational study
(59/91) 2 Different types of
s tins were recorded
2. Retrospective study
3. Statin users also
used more warfarin
derivates and
angiotensin II
antagonists
4. Amongst cases a
wide range of different
statin types was used
Continued
Sm
all
A
b
d
o
m
in
al
A
o
rtic
A
n
eu
rysm
s
707.
ia
e
lt
.
e
ni
n
he
eg
.
nﬂ
n
A
.
ta
Table 1-continued
First author/trial Year Intervention Study design Participants
(Cases/Controls)
Outcomes Signiﬁcance Strobe
score
Study qualities Study limitations
5. Statins were not
randomly assigned
6. Power calculation
missing
Sukhija29 2006 Statins Prospective case
control study
Total: 130 AAA size changes from
baseline(mm) until
endpoint:
p < .001 1. Measurements were
consistently made with
CT scan
1. Observational study
(75/55) Cases: 4.6 to 4.5 2. Power calculation
missing
Controls: 4.5 to 5.3
Meij, van der30 2013 Statins Retrospective
case control
study
Total: 142 No growth data available NS 1. Single observer
measurements only
1. Signiﬁcant
differences in baseline
characteristics and
cardiovascular risk
management between
cases and controls
(103/39) 2. Growth data missing
3. Non-randomized
4. Power calculation
missing
Ferguson31 2010 Prospective
cohort study
Total: 652 1. Sample size
calculations were
made
1. Observational study
Statins (349/303) Statins: OR 1.23 (95% CI
0.86e1.76)
NS 2. Different types of
statins were recorded
2. Growth data missing
Aspirin (363/289) Aspirin: OR 1.10 (95% CI
0.78e1.56)
NS 3. Signiﬁcant
differences in baseline
characteristics
Beta blockers (182/470) Beta blockers: OR 1.13
(95% CI 0.76e1.67)
NS
ACE inhibitors (242/410) ACE inhibitors: OR 0.91
(95% CI 0.64e1.31)
NS
Morosin32 2008 Statins Retrospective
case control
study
Total: 121 AAA diameter growth
(mm/y)
NS 1. No randomization
(34/87) Cases: 1.9 2. Power calculation
missing
Controls: 2.6
Vammen13 2001 Roxithromycin RCT Total: 58 AAA diameter growth
(mm/y)
p ¼ .02 1. Roxithromycin was
randomly assigned
1. Power calculation
missing
(27/31) Cases: 1.56 2. Well deﬁned
exclusion criteria
Controls: 2.75
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Hogh33 2009 Roxithromycin RCT Total: 84 AAA diameter growth
(mm/y)
NS 1. Roxithromycin was
randomly assigned
1. Power calculation
missing
(42/42) Cases: 1.61 2. Single observer
measurements only
2. Possible selection
bias as only one third
of the eligible AAAs
was included
Controls: 2.52
Karrlson34 2009 Azithromycin RCT Total: 213 AAA diameter growth
(mm/y)
NS 1. Azithromycin was
randomly assigned
1. Power calculation
missing
(106/105) Cases: 2.2 2. In addition to
ultrasound, for each
patient a volume
calculation was made
by CT scan
2. Differences in
baseline characteristics
Controls: 2.2
Aspirin Retrospective
case control
(101/100) Cases: 1.8 p ¼ .004 1. Observational study
Controls: 2.6 2. Retrospective study
Morosin35 2001 Doxycycline RCT Total: 32 AAA diameter growth
(mm/y)
NS 1. Single observer
measurements only
1. Power calculation
missing
(17/15) Cases: 1.5 2. Doxycycline was
randomly assigned
2. 3 month
intervention
Controls: 3.0 3. Major differences in
baseline AAA size
between the groups
Baxter36 2002 Doxycycline Prospective
cohort study
Total: 36 AAA diameter (mm) NS 1. Missing control
group
At baseline:
41.0 mm  0.9 mm
2. Treatment period 6
months
At 6 months: 42
.7 mm  1.3 mm
3. Power calculation
missing
Meijer37 2014 Doxycycline RCT Total: 286 AAA diameter growth (in
18 months)
p ¼ .016 1. Single observer
measurements only
1. High number of
elective repairs
(144/142) Cases: 4.1 mm (95% CI,
3.6 to 4.5 mm)
2. Doxycycline or
placebo were
randomly assigned
2. Doxycycline dose of
100 mg was possibly
too low or too high
Controls: 3.3 mm (CI, 2.8
to 3.7 mm)
3. Long-term
treatment with
doxycycline
3. Drop outs where
not followed
4. Valid power
calculation
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Table 1-continued
First author/trial Year Intervention Study design Participants
(Cases/Controls)
Outcomes Signiﬁcance Strobe
score
Study qualities Study limitations
Sillesen38 2014 Mast cell
inhibitor
(CD007)
RCT Total: 326 AAA diameter growth
(mm/y)
NS 1. Mast Cell Inhibitor
was randomly assigned
1. No proof for an
effect on the
aneurysm wall
10 mg (80/84) Cases (10 mg): 2.58 2. AAA diameter was
measured via 2D
Ultrasound
2. Power calculation
missing
25 mg (78/84) Cases (25 mg): 2.33 3. Long-term
treatment with the
mast cell inhibitor
40 mg (84/84) Cases (40 mg): 2.70
Controls: 2.04
Lindholt39 2008 Prospective case
control study
Total: 148 AAA diameter growth
(mm/y)
1. Overall growth data
not available
Aspirin AAA baseline <40 mm: AAA baseline
<40 mm: NS
2. Observational study
Cases: 2.52 3. Contradictory
conclusions for small
and intermediate AAA
Controls: 2.23 4. Power calculation
missing
Aspirin AAA baseline >40
e50 mm:
AAA baseline
>40e50 mm:
p ¼ .017
5. Self reported aspirin
use
Cases: 2.92
Controls: 5.18
Franklin40 1999 NSAIDs Unclear case
control study
Total: 78 AAA diameter growth
(mm/y)
p ¼ .004 1. Matched cases and
controls
1. Conference abstract
only
(19/59) Cases: 1.8 2. Unclear study
design
Controls: 3.2
NS ¼ not signiﬁcant.
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Small Abdominal Aortic Aneurysms 711implying that ACE inhibitors may adversely affect AAA
growth.23
Other anti hypertensive drugs (i.e. diuretics and calcium
channel blockers) were evaluated in two retrospective an-
alyses by Wilmink et al.16 and Bhak et al.19 Both studies
found no association between these antihypertensive
agents and AAA growth rate.
Statins
A potential effect of statins on AAA progression was eval-
uated in 12 studies. Six studies reported a beneﬁcial effect
of statin use on the AAA growth.24e29 In contrast, six other
reports failed to show an effect of statins on AAA
growth.22,23,30e32 Eight out of the 12 studies had a pro-
spective design, but none of them were randomized clinical
trials.19,22,24,26,27,29e31 Most studies did not specify the type
of statin investigated. Simvastatin and Atorvastatin were
the dominant statins in the four studies that speciﬁed the
statin type.28e31
There is an apparent paradox in conclusions for an effect
of statins, with the earlier small studies reporting an asso-
ciation between the statin use and reduced AAA expan-
sion,27e29 but the more recent studies failed to conﬁrm a
relationship.24,25,30 Moreover, none of the larger studies
(including more than 250 patients) found a difference in
AAA expansion rate between statin users and non-statin
users.22,23,31
Macrolides
A presumed role for chlamydia in AAA growth led to studies
testing an effect of macrolide treatment on the growth rate
of small AAAs. Two RCTs evaluated the effect of roxi-
thromycin on the expansion rate. The ﬁrst, conducted in
2001, reported a signiﬁcantly lower expansion rate in the
roxithromycin treated patients (p ¼ .02).13 The second
study, also a small RCT, reported a borderline effect of a 4
week treatment with roxithromycin on AAA progression
(p ¼ .055).33 The effect of azithromycin, another member of
the macrolide class, was investigated in a larger RCT con-
ducted by Karlsson et al.34 in 2009 (n ¼ 247). This study did
not observe a signiﬁcant difference between the AAA
expansion rate in the azithromycin treated patients and
controls.
Tetracyclines
In 2001, a small RCT showed a pronounced effect of 3
months of doxycycline treatment on AAA expansion for the
6e12 and 12e18 month follow up periods.35 Next, a phase
II open safety and feasibility study by Baxter et al.36
revealed signiﬁcant reduction in MMP9 levels after 6
months of doxycycline treatment. Nevertheless, no signiﬁ-
cant change was seen for the overall AAA expansion rate.
Results from an adequately powered multicenter RCT failed
to show a beneﬁcial effect of 18 months of doxycycline
therapy on AAA progression. On the contrary, acceleration
in AAA growth rate was reported during the 18 month
follow up period.37Anti-mast cell therapy
Sillesen et al.38 investigated whether the mast cell inhibitor
CRD007 (pemirolast) halted growth of small AAA. However,
no difference in AAA growth rate was found between pla-
cebo and the mast cell inhibitor treated patients.
Anti-platelet therapy
Five studies investigated the potential of anti-platelet
therapy in stabilizing human AAA growth.19,23,31,34,39 A
ﬁrst case control study including 167 patients reported a
decrease in AAA progression in those patients with a
diameter between 40 and 49 mm. Patients with an AAA
diameter smaller than 4.0 cm had a similar expansion rate
with or without using aspirin.39 Signiﬁcantly reduced AAA
progression in patients using aspirin was reported in a sub-
analysis of case control data of a small RCT investigating the
effect of azithromycin. The average growth rate of the 101
patients using aspirin was 1.8 mm/year compared with
2.6 mm/year in those not on antiplatelet therapy
(p < .01).34 In contrast analyses performed on patients
participating in the UK small aneurysm trial,23 the ADAM
study,19 and a cohort study incorporating 363 patients31
failed to identify an effect of platelet therapy on aneu-
rysm progression.
One small study (n ¼ 19) investigated the effect of non-
steroidal anti-inﬂammatory drugs (NSAIDs) on AAA
growth.40 The median growth rate of the AAA diameter of
1.8 mm/year compares favorably to the 3.2 mm/year in
patients not taking NSAIDs, p < .01.
DISCUSSION
This systematic review shows that the number of studies
evaluating a potential effect of pharmaceutical strategies to
halt AAA growth in humans is limited. The majority of
identiﬁed studies were of moderate quality, and initial
promising reports were not conﬁrmed by later larger
studies. At this point, no pharmaceutical therapy can be
recommended for the stabilization of AAA.
The search strategies identiﬁed 27 original papers that
evaluated the potential of pharmaceutical intervention for
AAA stabilization. Identiﬁed interventions can be subdivided
into strategies that are part of general cardiovascular risk
management (antihypertensive agents, statins, anti-platelet
therapy), and into “anti-inﬂammatory” strategies: macro-
lides, tetracyclines, and mast cell inhibition.
The majority of studies were of moderate quality, as
illustrated by a low to moderate score in the STROBE
scoring system.9 Most studies had a retrospective design,
and small sample size.41 Interpretation is hampered by poor
matching, lack of standardized diameter measurements,
and inappropriate statistical analyses. Studies on longitu-
dinal data such as aneurysm progression are prone to non-
random drop out.42 For example, older patients are more
likely to drop out because of death, but are less likely to
undergo repair due to different risk estimates. By the same
token, patients with larger or fast growing AAA are more
likely to drop out prematurely because of repair. As such
712 V.B.C. Kokje et al.follow up studies in AAA patients require speciﬁc statistical
approaches,43 a prerequisite that was not met in most
studies. Moreover, it was observed that initial promising
studies from small cohorts were not conﬁrmed by later
larger studies, an observation hinting at the phenomenon of
selective reporting.44
Most data are available for cardiovascular risk manage-
ment (beta blockers, ACE inhibitors and statins). Trials with
the beta blocker propranolol experienced high drop out
rates because of poor tolerance.14,15 Statins and ACE in-
hibitors are well tolerated, yet a recent meta-analysis on the
available data concluded that these drug classes did not
inﬂuence AAA progression.45
The second of the tested interventions was the anti-
inﬂammatory group, with anti-inﬂammatory referring to
an anti-microbial action, in the case of AAA because of a
suspected causative role for chlamydia infection in the
disease, or alternatively anti-inﬂammatory in the context of
chronic tissue inﬂammation that is thought to drive AAA
progression (doxycycline, mast cell inhibition).46 Although
aspirin has anti-inﬂammatory properties, it is unclear
whether the dose used for anti-platelet therapy is sufﬁcient
to exert an anti-inﬂammatory effect on the aneurysm wall.
Again, there was no evidence for a beneﬁcial effect of anti-
inﬂammatory strategies on AAA progression. On the con-
trary, evidence was found for growth acceleration in pa-
tients taking doxycycline.37
The above conclusions contrast sharply with the available
preclinical evidence that shows that pharmaceutical inter-
ference with aspects of the RAS system, cholesterol meta-
bolism, vascular inﬂammation or protease activity alleviates
aneurysm formation in rodent models of the disease4,5; an
observation pointing to impaired translatability of the
available preclinical models.46
In conclusion, there is currently no established medical
therapy for the stabilization of growing AAA. Interpretation
of the available data is hampered by its moderate quality. A
role for beta blockers, doxycycline, and the mast cell in-
hibitor pemirolast has been ruled out in RCTs. Available
observational data for ACE inhibitors and statins is not
consistent with a beneﬁcial effect on aneurysm progression.
A number of interventions are currently being evaluated in
clinical trials (Table 2). At this moment, no therapy can be
recommended although it cannot be excluded that AAATable 2. Overview of ongoing clinical trials.
Name Intervention Estimated
completion date
Clinical trial
number
PISA Antihypertensives December 2013 NCT01425242
AARDVARK ACE inhibitors October 2014 NCT01118520
ACZ885 Canakinumab
(anti IL1-beta)
December 2015 NCT02007252
TicAAA Ticagrelor December 2015 NCT02070653
TEDY Telmisartan August 2016 NCT01683084
BASE ACE vs. beta
blockers
October 2016 NCT01904981
N-TA
ˇ
3CT Doxycycline June 2017 NCT01756833
ACA4 Ciclosporin A September 2018 NCT02225756growth and rupture are disparate processes. Consequently
although some interventions do not inﬂuence AAA pro-
gression, they may inﬂuence the AAA rupture rate,47 a
notion that requires independent conﬁrmation. Moreover,
although cardiovascular risk management does not inﬂu-
ence AAA progression, it is important to point out that risk
management is indicated in AAA patients as this group is at
an extremely high cardiovascular risk.2
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